John Steele
Director Voyager Therapeutics Inc
Seminars
Thursday 10th September 2026
Fireside Chat: Balancing Immune Evasion with Safety Controls to Prevent Oncogenic Outgrowth & Improve Preclinical Risk Predictability
2:00 pm
- Assessing how iPSC‑derived cells may evade or escape immune surveillance, and the implications for uncontrolled proliferation in vivo
- Integrating kill‑switches, regulated elimination systems, and early oncogenicity assays to counter immune‑escape driven safety concerns
- Designing preclinical studies that separate acceptable immune evasion for persistence from high‑risk profiles that could trigger CRS, ICANS or tumor‑like expansion
